Investment Analysts’ Weekly Ratings Updates for Harmony Biosciences (HRMY)

Several brokerages have updated their recommendations and price targets on shares of Harmony Biosciences (NASDAQ: HRMY) in the last few weeks:

• 11/8/2026 – Harmony Biosciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/31/2026 – Harmony Biosciences was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 10/29/2026 – Harmony Biosciences was given a new $49.00 price target by Mizuho.
• 10/23/2026 – Harmony Biosciences was upgraded by WBB Securities to “hold”.
• 10/19/2026 – Harmony Biosciences had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $50.00 price target on the stock.
• 10/15/2026 – Harmony Biosciences was upgraded by Zacks Research from “hold” to “strong-buy”.
• 10/15/2026 – Harmony Biosciences is now covered by LADENBURG THALM/SH SH. They set a “buy” rating and a $55.00 price target on the stock.
• 10/13/2026 – Harmony Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $55.00 price target on the stock.
• 10/12/2026 – Harmony Biosciences was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 10/12/2026 – Harmony Biosciences had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $50.00 price target on the stock.
• 10/1/2026 – Harmony Biosciences had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $42.00 price target on the stock.
• 9/24/2026 – Harmony Biosciences had its “outperform” rating reaffirmed by Oppenheimer.

Harmony Biosciences Price Performance

Shares of Harmony Biosciences stock traded up $0.50 during midday trading on Monday, reaching $33.61. The company had a trading volume of 290,483 shares, compared to its average volume of 895,480. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of 11.13, a price-to-earnings-growth ratio of 0.27 and a beta of 1.00. Harmony Biosciences Holdings, Inc. has a 1-year low of $25.90 and a 1-year high of $43.49. The stock has a fifty day simple moving average of $39.36 and a 200 day simple moving average of $34.70. The company has a current ratio of 3.44, a quick ratio of 3.42 and a debt-to-equity ratio of 0.12.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.81 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.28). Harmony Biosciences had a net margin of 18.05% and a return on equity of 18.55%. The firm had revenue of $268.92 million during the quarter, compared to the consensus estimate of $272.05 million. During the same quarter last year, the firm earned $1.08 earnings per share. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 3.69 earnings per share for the current year.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, insider Kumar Budur sold 35,852 shares of the firm’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $43.05, for a total value of $1,543,428.60. Following the transaction, the insider directly owned 13,115 shares of the company’s stock, valued at approximately $564,600.75. This trade represents a 73.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 72,406 shares of company stock valued at $3,108,520. Company insiders own 11.00% of the company’s stock.

Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs.

Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019.

Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S.